A potential Ebola vaccine developed by GlaxoSmithKline in partnership with the National Institutes of Health showed promise during recent Phase 1 clinical testing.
Researchers at Okairos, which is owned by GlaxoSmithKline, used chimpanzee adenovirus type 3, a type of chimpanzee cold virus, to deliver genetic material from the Sudan and Zaire strains of the Ebola virus to adult volunteers participating in the study. The vaccine produced an immunological response and was tolerated by 20 study participants, a report published in Wednesday's "New England Journal of Medicine" stated.
“It’s important to remember that these data are the first piece in the jigsaw and we’re continuing to gather other important information," GSK Chairman of Global Vaccines Dr. Moncef Slaoui said. "Over the coming weeks, we will see results from further Phase 1 trials, which will tell us more about the profile of the monovalent vaccine – most significantly results from a trial in Mali, which is assessing its safety and immune response in West African populations."
If data from all the initial trials are positive, Slaoui said the next phase of testing would look into weather the immune responses witnessed in Phase 1 testing translates to actual protection against Ebola.
The next phase of testing is scheduled to begin in early 2015.